Because EDNRB has been proposed to serve as a negative regulator of endothelin A receptor signaling (EDNRA) 5,9, and considering that EDNRA is a well-known promoter of breast cancer progression 19, EDNRB is expected to be an antagonist to breast cancer. Here, EDNRA is linked to breast carcinoma.